The Cure That Harms: How Bad Medication for Chronic Illness Fuels a Silent Epidemic of Superbugs
Bad Medication
DOI:
https://doi.org/10.33687/ricosbiol.03.010.84Keywords:
secondary bacterial infection, Antimicrobial Resistance, superbugs, osteomyelitis, immunosuppression, antimicrobial stewardship, microbiome, chronic disease managementAbstract
The global rise in chronic diseases represents a significant public health burden. While the primary management of these conditions is paramount, a growing body of evidence highlights a dangerous and often overlooked consequence: the increased risk of secondary bacterial infections. This risk is profoundly exacerbated by the inappropriate medication of the underlying chronic disease. Inappropriate medication includes the misuse of antibiotics, immunosuppressive agents, corticosteroids, and broad-spectrum therapies that disrupt the microbiome. These pharmacological missteps can lead to immunosuppression, microbial dysbiosis, and the selection of drug-resistant pathogens, creating a fertile ground for secondary infections. This review synthesizes current literature to explore the mechanisms including immunosuppression, microbiome disruption, and antimicrobial resistance by which poor pharmacologic management of chronic diseases such as diabetes, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and inflammatory bowel disease predisposes patients to serious secondary bacterial infections, with a special focus on devastating bone and joint complications. It also discusses the clinical implications, common causative pathogens, and proposes strategies for mitigation, emphasizing antimicrobial stewardship and personalized medicine to break this dangerous cycle.
Downloads
References
Barton, K. D., Kavanagh, N., O'Connell, B., O'Toole, M., O'Sullivan, T., and O'Brien, F. J. (2023). Risk factors for treatment failure in patients with chronic osteomyelitis: A retrospective cohort study. Journal of Bone and Joint Infection, 8(1), 35-44. https://doi.org/10.5194/jbji-8-35-2023
Bersoff-Matcha, S. J., Chamberlain, C., Cao, C., Kortepeter, C., and Chong, W. H. (2019). Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. Annals of Internal Medicine, 170(11), 764–769. https://doi.org/10.7326/M19-0085
Buehrle, D. J., Wagener, M. M., Nguyen, M. H., and Clancy, C. J. (2020). Impact of an antimicrobial stewardship program-bundled initiative utilizing advanced molecular diagnostics for carbapenem-resistant Gram-negative bacterial infections. Open Forum Infectious Diseases, 7(7), ofaa227. https://doi.org/10.1093/ofid/ofaa227
Cohen, S. B., Koenig, A., Wang, L., Kwok, K., Mebus, C. A., and Riese, R. (2021). The safety profile of tofacitinib in patients with rheumatoid arthritis: A post-hoc analysis of laboratory parameters and infectious events. Rheumatology and Therapy, 8(1), 281-296. https://doi.org/10.1007/s40744-020-00267-8
Dickens, J. A., Miller, B. E., Edwards, L. D., Silverman, E. K., Lomas, D. A., and Tal-Singer, R.; ECLIPSE Investigators. (2021). COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respiratory Research, 22(1), 86. https://doi.org/10.1186/s12931-021-01682-3
Feldstein, D. A., Ogden, R., Hohmann, S. F., and Kopp, B. J. (2021). A multifaceted antimicrobial stewardship program for the treatment of uncomplicated cystitis in the emergency department. Journal of Pharmacy Practice, 34(4), 545-550. https://doi.org/10.1177/0897190019876498
Huang, D. T., McCreary, E. K., Bariola, J. R., Wadas, R. J., Kip, K. E., Marroquin, O. C., Collins, T., Schmid, A., Yealy, D. M., and Angus, D. C. (2021). The efficacy and safety of procalcitonin guidance in antibiotics discontinuation in sepsis: A systematic review and meta-analysis of randomized controlled trials. Critical Care Medicine, 49(7), 1119-1131. https://doi.org/10.1097/CCM.0000000000004947
Ianiro, G., Mullish, B. H., Kelly, C. R., Kassam, Z., Kuijper, E. J., Ng, S. C., and Zhang, F. (2020). Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut, 69(9), 1555-1563. https://doi.org/10.1136/gutjnl-2020-321829
Larsson, D. G. J., and Flach, C. F. (2022). Antibiotic resistance in the environment. Nature Reviews Microbiology, 20(5), 257–269. https://doi.org/10.1038/s41579-021-00649-x
Lázaro-Martínez, J. L., García-Madrid, M., García-Álvarez, Y., and Álvaro-Afonso, F. J. (2021). The role of biomarkers in the diagnosis and management of diabetic foot osteomyelitis: A systematic review. Journal of Clinical Medicine, 10(14), 3027. https://doi.org/10.3390/jcm10143027
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., and Kim, H. (2013). A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma, and Clinical Immunology, 9(1), 30. https://doi.org/10.1186/1710-1492-9-30
Masters, E. A., Ricciardi, B. F., Bentley, K. L. M., Moriarty, T. F., Schwarz, E. M., and Muthukrishnan, G. (2021). Skeletal infections: Microbial pathogenesis, immunity and clinical management. Nature Reviews Microbiology, 20(7), 385–400. https://doi.org/10.1038/s41579-022-00686-0
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... and Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
Nelson, R. E., Hatfield, K. M., Wolford, H., Samore, M. H., Scott, R. D., Reddy, S. C., ... and Baggs, J. (2021). National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clinical Infectious Diseases, 72(Suppl 1), S17–S26. https://doi.org/10.1093/cid/ciaa1581
Ng, K. M., Aranda-Díaz, A., Tropini, C., Frankel, M. R., Van Treuren, W., O'Laughlin, C. T., ... and Sonnenburg, J. L. (2023). Recovery of the gut microbiota after antibiotics depends on host diet, community context, and environmental reservoirs. Cell Host and Microbe, 31(4), 519-533.e6. https://doi.org/10.1016/j.chom.2023.02.008
Pujades-Rodriguez, M., Morgan, A. W., Cubbon, R. M., and Wu, J. (2020). Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases. Circulation, 142(11), 1059-1062. https://doi.org/10.1161/CIRCULATIONAHA.119.044794
Rutherford, A. I., Subesinghe, S., Hyrich, K. L., and Galloway, J. B. (2022). Serious infection across biologic-treated patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 81(4), 542-548. https://doi.org/10.1136/annrheumdis-2021-221304
Sakharkar, P., Bounthavong, M., and Hirsch, J. D. (2022). A systematic review of the impact of antimicrobial dosing strategies on resistance development in patient-level models. Infection and Drug Resistance, 15, 983–996. https://doi.org/10.2147/IDR.S347641
Talsania, M., Scofield, R. H., and Menzies, H. (2021). Septic arthritis in inflammatory arthritis: A challenging diagnostic dilemma. Therapeutic Advances in Musculoskeletal Disease, 13, 1759720X211015003. https://doi.org/10.1177/1759720X211015003
Uçkay, I., Gariani, K., Dubois-Ferriere, V., Suvà, D., and Lipsky, B. A. (2020). Diabetic foot infections: Recent advances and future prospects. Diabetes Therapy, 11(11), 2527–2545. https://doi.org/10.1007/s13300-020-00930-x
Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., ... and Weersma, R. K. (2020). Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications, 11(1), 362. https://doi.org/10.1038/s41467-019-14177-z
World Health Organization. (2022, June 22). Noncommunicable diseases. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases
Xie, W., Huang, Y., Xiao, S., Sun, X., Fan, Y., and Zhang, Z. (2022). Risk of serious infections in rheumatoid arthritis patients treated with biologics and tofacitinib: A systematic review and meta-analysis. Frontiers in Immunology, 13, 858757. https://doi.org/10.3389/fimmu.2022.858757
Published
Data Availability Statement
Copyright: Copyrights retained to the Authors., Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/),which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/public domain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Issue
Section
Categories
License
Copyright (c) 2025 Hussein Abouelhag
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
